The Meals and Drug Administration (FDA) has issued a breakthrough system designation to Sonire Therapeutics for using its high-intensity targeted ultrasound (HIFU) system (Suizenji) to deal with pancreatic most cancers, a illness which will declare the lives of 51,750 individuals in the US in 2024, in line with estimates from the American Most cancers Society.1,2
By using cavitation ultrasound, Sonire Therapeutics mentioned the Suizenji HIFU system facilitates the supply of thermal remedy with decrease acoustic vitality along with offering picture readability for focused remedy.3
The high-intensity targeted ultrasound (HIFU) system Suizenji (Sonire Therapeutics) has garnered the FDA’s breakthrough system designation for pancreatic most cancers remedy. The HIFU system is presently being evaluated in a section 2 trial for the remedy of sufferers with unresectable pancreatic most cancers refractory or illiberal to preliminary chemotherapy. (Picture courtesy of Sonire Therapeutics.)
“These are key options to attain each security and remedy throughput in our system,” famous Tohru Satoh, the chief government officer of Sonire Therapeutics, in a 2023 interview.3
Researchers are presently evaluating adjunctive use of the rising HIFU system with second-line chemotherapy versus chemotherapy alone in a section 2 trial for the remedy of sufferers with unresectable pancreatic most cancers refractory or illiberal to preliminary chemotherapy, in line with Sonire Therapeutics.
References
1. Sonire Therapeutics. Sonire’s HIFU remedy system designated as breakthrough system by FDA. PR Newswire. Out there at: https://www.prnewswire.com/news-releases/sonires-hifu-therapy-system-designated-as-breakthrough-device-by-fda-302277187.html . Printed October 16, 2024. Accessed October 16, 2024.
2. American Most cancers Society. Key statistics for pancreatic most cancers. Out there at: https://www.most cancers.org/most cancers/sorts/pancreatic-cancer/about/key-statistics.html#:~:textual content=Thepercent20averagepercent20lifetimepercent20riskpercent20of,Cancerpercent20Survivalpercent20Ratespercent20bypercent20Stage. . Accessed October 16, 2024.
3. Targeted Ultrasound Basis. Firm profile: Sonfire Therapeutics. Out there at: https://www.fusfoundation.org/posts/company-profile-sonire-therapeutics/#:~:textual content=Wepercent20spokepercent20withpercent20thepercent20SONIRE’s,whatpercent20makespercent20theirpercent20devicepercent20unique. . Printed February 22, 2023. Accessed October 16, 2024.
